Tsumura Past Earnings Performance
Past criteria checks 2/6
Tsumura has been growing earnings at an average annual rate of 4.3%, while the Pharmaceuticals industry saw earnings growing at 1% annually. Revenues have been growing at an average rate of 4% per year. Tsumura's return on equity is 6.3%, and it has net margins of 11.3%.
Key information
4.3%
Earnings growth rate
4.3%
EPS growth rate
Pharmaceuticals Industry Growth | 6.0% |
Revenue growth rate | 4.0% |
Return on equity | 6.3% |
Net Margin | 11.3% |
Next Earnings Update | 09 May 2024 |
Recent past performance updates
Recent updates
Revenue & Expenses BreakdownBeta
How Tsumura makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
---|---|---|---|---|
31 Dec 23 | 148,793 | 16,758 | 40,850 | 7,594 |
30 Sep 23 | 145,238 | 13,598 | 40,852 | 7,594 |
30 Jun 23 | 142,662 | 14,182 | 40,179 | 7,594 |
31 Mar 23 | 140,043 | 16,482 | 39,771 | 7,594 |
31 Dec 22 | 138,240 | 19,322 | 40,057 | 7,313 |
30 Sep 22 | 136,237 | 20,760 | 38,896 | 7,313 |
30 Jun 22 | 132,192 | 20,079 | 38,055 | 7,313 |
31 Mar 22 | 129,546 | 18,836 | 36,775 | 7,313 |
31 Dec 21 | 129,783 | 17,365 | 39,879 | 6,631 |
30 Sep 21 | 130,305 | 17,214 | 43,656 | 6,631 |
30 Jun 21 | 130,886 | 16,676 | 46,567 | 6,631 |
31 Mar 21 | 130,883 | 15,332 | 48,917 | 6,631 |
31 Dec 20 | 127,545 | 15,431 | 48,063 | 6,270 |
30 Sep 20 | 126,440 | 14,811 | 47,493 | 6,270 |
30 Jun 20 | 124,317 | 13,907 | 46,980 | 6,270 |
31 Mar 20 | 123,248 | 13,765 | 47,353 | 6,270 |
31 Dec 19 | 124,081 | 14,552 | 47,565 | 5,926 |
30 Sep 19 | 123,440 | 14,548 | 47,359 | 5,926 |
30 Jun 19 | 121,829 | 14,980 | 47,258 | 5,926 |
31 Mar 19 | 120,906 | 14,593 | 47,009 | 5,926 |
31 Dec 18 | 118,978 | 13,933 | 46,482 | 6,048 |
30 Sep 18 | 117,865 | 14,972 | 46,065 | 6,048 |
30 Jun 18 | 118,587 | 14,826 | 45,712 | 6,048 |
31 Mar 18 | 117,879 | 14,504 | 45,176 | 6,048 |
31 Dec 17 | 117,906 | 13,627 | 44,899 | 6,087 |
30 Sep 17 | 116,877 | 13,791 | 44,088 | 6,087 |
30 Jun 17 | 115,330 | 12,730 | 43,758 | 6,087 |
31 Mar 17 | 114,954 | 12,488 | 43,429 | 6,087 |
31 Dec 16 | 114,022 | 13,079 | 42,456 | 5,968 |
30 Sep 16 | 114,424 | 11,330 | 42,329 | 5,968 |
30 Jun 16 | 114,557 | 12,373 | 42,038 | 5,968 |
31 Mar 16 | 112,625 | 12,557 | 41,775 | 5,968 |
31 Dec 15 | 111,986 | 12,550 | 42,267 | 6,252 |
30 Sep 15 | 112,288 | 14,485 | 42,440 | 6,252 |
30 Jun 15 | 110,570 | 14,206 | 42,694 | 6,252 |
31 Mar 15 | 110,438 | 14,075 | 42,835 | 6,252 |
31 Dec 14 | 112,445 | 15,407 | 42,536 | 5,949 |
30 Sep 14 | 109,369 | 17,109 | 42,499 | 5,949 |
30 Jun 14 | 110,187 | 17,248 | 42,616 | 5,949 |
31 Mar 14 | 110,057 | 18,050 | 42,859 | 5,949 |
31 Dec 13 | 107,821 | 18,023 | 43,756 | 4,904 |
30 Sep 13 | 107,988 | 15,558 | 43,200 | 4,904 |
30 Jun 13 | 106,103 | 15,373 | 42,358 | 4,904 |
Quality Earnings: TSMR.F has high quality earnings.
Growing Profit Margin: TSMR.F's current net profit margins (11.3%) are lower than last year (14%).
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: TSMR.F's earnings have grown by 4.3% per year over the past 5 years.
Accelerating Growth: TSMR.F's has had negative earnings growth over the past year, so it can't be compared to its 5-year average.
Earnings vs Industry: TSMR.F had negative earnings growth (-13.3%) over the past year, making it difficult to compare to the Pharmaceuticals industry average (-13.2%).
Return on Equity
High ROE: TSMR.F's Return on Equity (6.3%) is considered low.